# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-205182
Filing Date
2026-05-05
Accepted
2026-05-05 08:30:37
Documents
57
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | nerv-20260331.htm iXBRL | 10-Q | 1463853
2 | EX-31.1 | nerv-ex31_1.htm | EX-31.1 | 16586
3 | EX-31.2 | nerv-ex31_2.htm | EX-31.2 | 16116
4 | EX-32.1 | nerv-ex32_1.htm | EX-32.1 | 14485
| Complete submission text file | 0001193125-26-205182.txt |  | 7639768

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | nerv-20260331.xsd | EX-101.SCH | 1203321
61 | EXTRACTED XBRL INSTANCE DOCUMENT | nerv-20260331_htm.xml | XML | 1457736

Mailing Address 1500 DISTRICT AVENUE BURLINGTON MA 01803
Business Address 1500 DISTRICT AVENUE BURLINGTON MA 01803 617-600-7373
Minerva Neurosciences, Inc. (Filer) CIK: 0001598646 (see all company filings)

EIN.: 260784194 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36517 | Film No.: 26940687
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)